Palantir Technologies Inc. - Class A Common Stock (PLTR)
155.92
-2.51 (-1.58%)
NASDAQ· Last Trade: Aug 6th, 4:17 PM EDT
Detailed Quote
Previous Close
158.43
Open
155.87
Bid
155.75
Ask
155.91
Day's Range
152.70 - 158.00
52 Week Range
106.37 - 207.52
Volume
39,889,642
Market Cap
316.12B
PE Ratio (TTM)
251.48
EPS (TTM)
0.6
Dividend & Yield
N/A (N/A)
1 Month Average Volume
43,267,674
Chart
About Palantir Technologies Inc. - Class A Common Stock (PLTR)
Palantir Technologies is a public software company that specializes in big data analytics and provides platforms for organizations to integrate, visualize, and analyze large amounts of data from disparate sources. Its flagship products, Palantir Gotham and Palantir Foundry, are designed to assist government agencies and commercial enterprises in making data-driven decisions by offering advanced analytical capabilities, collaborative tools, and visualization features. The company has gained prominence for its work with intelligence and defense organizations, as well as its growing presence in various industries such as finance, healthcare, and manufacturing, enabling clients to derive actionable insights and enhance their operational efficiency. Read More
What Happened? Shares of food distribution giant US Foods (NYSE:USFD) jumped 6.8% in the afternoon session after Shares of US Foods climbed after the company...
What Happened? Shares of cloud monitoring platform Datadog (NASDAQ:DDOG) fell 17.6% in the afternoon session after the company issued third-quarter guidance ...
What Happened? Shares of biorefining company Green Plains (NASDAQ:GPRE) fell 7.9% in the afternoon session after the company reported a significant drop in s...
Global car rental company Hertz (NASDAQ:HTZ) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.7% year on year to $2.40 billion. Its non-...
Energy and industrial distributor DNOW (NYSE:DNOW) announced better-than-expected revenue in Q2 CY2026, with sales up 108% year on year to $1.31 billion. Its...
Vaccine biotechnology company Novavax (NASDAQ:NVAX) announced better-than-expected revenue in Q2 CY2026, but sales fell by 76.3% year on year to $56.7 millio...
Energy and construction materials company MDU Resources (NYSE:MDU) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.8% year on ...
Modern production environments face unprecedented risks from machine-speed cyber threats and automated exploits. Organizations increasingly adopt real-time
Beverage company Keurig Dr Pepper (NASDAQ:KDP) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 75.6% year on year to $7....
Payment processing company Shift4 Payments (NYSE:FOUR) announced better-than-expected revenue in Q2 CY2026, with sales up 34% year on year to $1.30 billion. ...
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 2.7% year on yea...
WW International (NASDAQ:WW), the parent company of Weight Watchers, reported second-quarter 2026 revenue of $162.3 million, down from $189.2 million a year earlier, while highlighting growth in its clinical and higher-value behavioral membership tiers and reaffirming its full-year financial outlook
Wireless telecommunications provider Array (NYSE:AD) will be announcing earnings results this Friday before the bell. Here’s what you need to know. Array mis...
Fast-food chain Wendy’s (NASDAQ:WEN) will be reporting results this Friday morning. Here’s what investors should know. Wendy's beat analysts’ revenue expecta...
Athletic apparel company Under Armour (NYSE:UAA) will be reporting results this Friday before market open. Here’s what you need to know. Under Armour met ana...
Civil infrastructure company Construction Partners (NASDAQ:ROAD) will be reporting earnings this Friday before market open. Here’s what to look for. Construc...
Oil and gas producer Occidental Petroleum (NYSE:OXY) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 52.1% year on year to $...
Genomics company Pacific Biosciences of California (NASDAQ:PACB) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 1.9% year o...
